Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity

Marta Ciszewicz, Alicja PoLubinska, Artur Antoniewicz, Katarzyna Suminska-Jasinska, Andrzej BrEborowicz

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Sulodexide is a mixture of heparin and dermatan sulfate with antithrombotic and profibrynolytic activity. Individual reports suggest the anti-inflammatory action of sulodexin. The goal of this study was to evaluate the effect of sulodexide on the release of the inflammatory mediators from endothelium in normal conditions and in cells chronically exposed to glucose. The experiments were performed on in vitro cultured human umbilical endothelial cells kept for 7 days in standard medium or in the same medium but supplemented with glucose 30 mmol/L. Sulodexide was added to the culture medium in concentrations of 0.125 lipase releasing unit (LRU)/mL, 0.25 LRU/mL, and 0.5 LRU/mL Spontaneous generation of oxygen-derived free radicals and the release of monocyte chemotactic protein-1 (MCP-1) and interleukin-6 (IL-6) from the studied cells was evaluated. Additionally, the healing of the injured mesothelium was studied in the presence of sulodexide and glucose. Sulodexide caused the inhibition of the intracellular generation of free radicals in a dose-dependent manner (maximally by 32%, P < 0.01), as well as the inhibition of MCP-1 (maximally by 60%, P < 0.001) and IL-6 (maximally by 69%, P < 0.01). Cells cultured in a medium with glucose 30 mmol/L generated more free radicals (+20%, P < 0.05) and released more MCP-1 (+113%, P < 0.001) and IL-6 (+26%, P < 0.05). Cell monolayers treated with glucose had a decreased ability to heal after mechanical injury (-28%, P < 0.001). All these glucose effects were reversed when cells were exposed to sulodexide simultaneously. The results of our study demonstrate a significant anti-inflammatory action of sulodexide in the endothelial cells and a protective effect of that drug against glucose cytotoxicity.

Original languageEnglish (US)
Pages (from-to)118-123
Number of pages6
JournalTranslational Research
Volume153
Issue number3
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Endothelial cells
Cytotoxicity
Endothelial Cells
Inflammation
Glucose
Chemokine CCL2
Lipase
Free Radicals
Interleukin-6
Anti-Inflammatory Agents
Umbilicus
Protective Agents
Dermatan Sulfate
glucuronyl glucosamine glycan sulfate
Endothelium
Culture Media
Heparin
Cultured Cells
Monolayers
Epithelium

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, medical
  • Public Health, Environmental and Occupational Health

Cite this

Ciszewicz, M., PoLubinska, A., Antoniewicz, A., Suminska-Jasinska, K., & BrEborowicz, A. (2009). Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Translational Research, 153(3), 118-123. https://doi.org/10.1016/j.trsl.2008.12.007

Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. / Ciszewicz, Marta; PoLubinska, Alicja; Antoniewicz, Artur; Suminska-Jasinska, Katarzyna; BrEborowicz, Andrzej.

In: Translational Research, Vol. 153, No. 3, 03.2009, p. 118-123.

Research output: Contribution to journalArticle

Ciszewicz, M, PoLubinska, A, Antoniewicz, A, Suminska-Jasinska, K & BrEborowicz, A 2009, 'Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity', Translational Research, vol. 153, no. 3, pp. 118-123. https://doi.org/10.1016/j.trsl.2008.12.007
Ciszewicz M, PoLubinska A, Antoniewicz A, Suminska-Jasinska K, BrEborowicz A. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Translational Research. 2009 Mar;153(3):118-123. https://doi.org/10.1016/j.trsl.2008.12.007
Ciszewicz, Marta ; PoLubinska, Alicja ; Antoniewicz, Artur ; Suminska-Jasinska, Katarzyna ; BrEborowicz, Andrzej. / Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. In: Translational Research. 2009 ; Vol. 153, No. 3. pp. 118-123.
@article{0807e6d61b4841a1a92a0d6dd6153694,
title = "Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity",
abstract = "Sulodexide is a mixture of heparin and dermatan sulfate with antithrombotic and profibrynolytic activity. Individual reports suggest the anti-inflammatory action of sulodexin. The goal of this study was to evaluate the effect of sulodexide on the release of the inflammatory mediators from endothelium in normal conditions and in cells chronically exposed to glucose. The experiments were performed on in vitro cultured human umbilical endothelial cells kept for 7 days in standard medium or in the same medium but supplemented with glucose 30 mmol/L. Sulodexide was added to the culture medium in concentrations of 0.125 lipase releasing unit (LRU)/mL, 0.25 LRU/mL, and 0.5 LRU/mL Spontaneous generation of oxygen-derived free radicals and the release of monocyte chemotactic protein-1 (MCP-1) and interleukin-6 (IL-6) from the studied cells was evaluated. Additionally, the healing of the injured mesothelium was studied in the presence of sulodexide and glucose. Sulodexide caused the inhibition of the intracellular generation of free radicals in a dose-dependent manner (maximally by 32{\%}, P < 0.01), as well as the inhibition of MCP-1 (maximally by 60{\%}, P < 0.001) and IL-6 (maximally by 69{\%}, P < 0.01). Cells cultured in a medium with glucose 30 mmol/L generated more free radicals (+20{\%}, P < 0.05) and released more MCP-1 (+113{\%}, P < 0.001) and IL-6 (+26{\%}, P < 0.05). Cell monolayers treated with glucose had a decreased ability to heal after mechanical injury (-28{\%}, P < 0.001). All these glucose effects were reversed when cells were exposed to sulodexide simultaneously. The results of our study demonstrate a significant anti-inflammatory action of sulodexide in the endothelial cells and a protective effect of that drug against glucose cytotoxicity.",
author = "Marta Ciszewicz and Alicja PoLubinska and Artur Antoniewicz and Katarzyna Suminska-Jasinska and Andrzej BrEborowicz",
year = "2009",
month = "3",
doi = "10.1016/j.trsl.2008.12.007",
language = "English (US)",
volume = "153",
pages = "118--123",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity

AU - Ciszewicz, Marta

AU - PoLubinska, Alicja

AU - Antoniewicz, Artur

AU - Suminska-Jasinska, Katarzyna

AU - BrEborowicz, Andrzej

PY - 2009/3

Y1 - 2009/3

N2 - Sulodexide is a mixture of heparin and dermatan sulfate with antithrombotic and profibrynolytic activity. Individual reports suggest the anti-inflammatory action of sulodexin. The goal of this study was to evaluate the effect of sulodexide on the release of the inflammatory mediators from endothelium in normal conditions and in cells chronically exposed to glucose. The experiments were performed on in vitro cultured human umbilical endothelial cells kept for 7 days in standard medium or in the same medium but supplemented with glucose 30 mmol/L. Sulodexide was added to the culture medium in concentrations of 0.125 lipase releasing unit (LRU)/mL, 0.25 LRU/mL, and 0.5 LRU/mL Spontaneous generation of oxygen-derived free radicals and the release of monocyte chemotactic protein-1 (MCP-1) and interleukin-6 (IL-6) from the studied cells was evaluated. Additionally, the healing of the injured mesothelium was studied in the presence of sulodexide and glucose. Sulodexide caused the inhibition of the intracellular generation of free radicals in a dose-dependent manner (maximally by 32%, P < 0.01), as well as the inhibition of MCP-1 (maximally by 60%, P < 0.001) and IL-6 (maximally by 69%, P < 0.01). Cells cultured in a medium with glucose 30 mmol/L generated more free radicals (+20%, P < 0.05) and released more MCP-1 (+113%, P < 0.001) and IL-6 (+26%, P < 0.05). Cell monolayers treated with glucose had a decreased ability to heal after mechanical injury (-28%, P < 0.001). All these glucose effects were reversed when cells were exposed to sulodexide simultaneously. The results of our study demonstrate a significant anti-inflammatory action of sulodexide in the endothelial cells and a protective effect of that drug against glucose cytotoxicity.

AB - Sulodexide is a mixture of heparin and dermatan sulfate with antithrombotic and profibrynolytic activity. Individual reports suggest the anti-inflammatory action of sulodexin. The goal of this study was to evaluate the effect of sulodexide on the release of the inflammatory mediators from endothelium in normal conditions and in cells chronically exposed to glucose. The experiments were performed on in vitro cultured human umbilical endothelial cells kept for 7 days in standard medium or in the same medium but supplemented with glucose 30 mmol/L. Sulodexide was added to the culture medium in concentrations of 0.125 lipase releasing unit (LRU)/mL, 0.25 LRU/mL, and 0.5 LRU/mL Spontaneous generation of oxygen-derived free radicals and the release of monocyte chemotactic protein-1 (MCP-1) and interleukin-6 (IL-6) from the studied cells was evaluated. Additionally, the healing of the injured mesothelium was studied in the presence of sulodexide and glucose. Sulodexide caused the inhibition of the intracellular generation of free radicals in a dose-dependent manner (maximally by 32%, P < 0.01), as well as the inhibition of MCP-1 (maximally by 60%, P < 0.001) and IL-6 (maximally by 69%, P < 0.01). Cells cultured in a medium with glucose 30 mmol/L generated more free radicals (+20%, P < 0.05) and released more MCP-1 (+113%, P < 0.001) and IL-6 (+26%, P < 0.05). Cell monolayers treated with glucose had a decreased ability to heal after mechanical injury (-28%, P < 0.001). All these glucose effects were reversed when cells were exposed to sulodexide simultaneously. The results of our study demonstrate a significant anti-inflammatory action of sulodexide in the endothelial cells and a protective effect of that drug against glucose cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=59849098642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849098642&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2008.12.007

DO - 10.1016/j.trsl.2008.12.007

M3 - Article

VL - 153

SP - 118

EP - 123

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 3

ER -